Company Overview of Novartis International AG
Novartis International AG offers research, development, manufacture, and marketing of pharmaceuticals. The company manufactures drugs such as clozapine (Clozaril), Jakavi (ruxolitinib), diclofenac (Voltaren), carbamazepine (Tegretol), valsartan (Diovan), imatinib mesylate and (Gleevec / Glivec). Additional agents include ciclosporin (Neoral / Sandimmun), letrozole (Femara), methylphenidate (Ritalin), terbinafine (Lamisil), and others. Novartis International AG is based in Basel, Switzerland. Novartis International AG operates as a subsidiary of Novartis AG.
Key Executives for Novartis International AG
Senior Vice President and Head of Corporate Strategy
Compensation as of Fiscal Year 2015.
Novartis International AG Key Developments
Novartis Announces Strategic Alliance and Licensing Agreement with Surface Oncology
Jan 11 16
Novartis announced that it is adding to its diverse and deep immuno-oncology pipeline through a strategic alliance and licensing agreement with Surface Oncology. The agreement gives Novartis access to four pre-clinical programs that target regulatory T cell populations, inhibitory cytokines, and immunosuppressive metabolites in the tumor microenvironment. These programs will be explored as monotherapies and in combination with other complementary therapies in Novartis' immuno-oncology and targeted therapy portfolios. At the start of 2015 Novartis launched a new immuno-oncology research team led by cancer vaccine pioneer Glenn Dranoff. In a short period of time, this team has rapidly built a broad portfolio of clinical and pre-clinical programs focused on stimulating the body's immune system to combat cancers through targeting critical regulatory steps in the anti-tumor immune response. The company's immuno-oncology portfolio includes novel checkpoint inhibitors, chimeric antigen receptor T-cell (CART) technology, myeloid cell targeting agents, the T cell stimulating factor IL-15, STING agonists that enhance immune recognition of cancers, and adenosine receptor antagonists and TGF-beta blocking antibodies that overcome immunosuppression in the tumor microenvironment. Seven of these candidates are already in clinical trials and five more are expected to enter the clinic individually and as combinations by the end of 2016. Novartis' myeloid cell targeting program (MCS110), anti-TIM-3 program (MGB453), IL-15- agonist (NIZ985) checkpoint inhibitors targeting PD-1 (PDR001) and LAG-3 (LAG525), and a small molecule adenosine receptor antagonist (NIR178) are now in phase 1 clinical trials. The CART program (CTL019) is in phase 2 clinical trials. A STING agonist (MIW815), a GITR agonist, and an anti-TGF-beta antibody are progressing toward first-in-human clinical trials in 2016. This rich immuno-oncology pipeline together with a deep targeted therapy portfolio provides Novartis with the opportunity to attack cancer in powerful and complementary ways: through enhancing immune-mediated tumor destruction and promoting direct tumor cell killing. Together, these synergistic approaches may accomplish more durable clinical benefits for a larger proportion of cancer patients.
Novartis International AG Announces Phase III Studies of Jakavi Show Disease Improvement in Patients with Myelofibrosis and Polycythemia Vera
Dec 5 15
Novartis International AG announced that five-year treatment with Jakavi (ruxolitinib) suggested an overall survival advantage for patients with myelofibrosis (MF), despite crossover to Jakavi from the best available therapy arm after the primary analysis at 48 weeks (intent-to-treat analysis: 33% reduction in risk of death, hazard ratio=0.67 [95% confidence interval (CI), 0.44-1.02], crossover-corrected hazard ratio=0.44 [95% CI, 0.18-1.04]). In the COMFORT-II (COntrolled MyeloFibrosis Study with ORal JAK Inhibitor Therapy) Phase III study, more than half of the patients with MF (53.4%) also experienced significant reductions (>=35%) in spleen size with Jakavi therapy, and sustained this benefit over prolonged periods of time (median duration of 3.2 years). Findings from this study were presented at the 57th American Society of Hematology Meeting (ASH) in Orlando, Florida. In addition to the Jakavi data presented at ASH, Novartis announced that a separate Phase III study met its primary endpoint-patients with polycythemia vera resistant to or intolerant of hydroxyurea who did not have an enlarged spleen who were treated with Jakavi maintained hematocrit control without the need for phlebotomy. In the Phase III RESPONSE 2 (Randomized Study of Efficacy and Safety in POlycythemia Vera with JAK INhibitor Ruxolitinib VerSus BEst Available Care) study, the safety profile of Jakavi was consistent with previous studies. Full results from the trial continue to be evaluated and will be presented at a future medical congress. In the Phase III trial, fibrosis grades, a key indicator of disease control in MF, improved (15.8%) or were maintained (32.2%) in nearly half of patients with long-term Jakavi treatment. Nearly one-quarter of patients (26.7% from Jakavi treatment arm; 24.4% who crossed over from best available treatment arm) remained on treatment with Jakavi for five years. All adverse events were consistent with previous analyses of treatment with Jakavi in patients with MF. The most common AEs in Jakavi-treated patients either after randomization or after crossing over from best available therapy were thrombocytopenia (52.4%), anemia (49.2%), diarrhea (35.6%) and peripheral edema (33.0%). The most common grade 3/4 AEs included anemia (22.5%), thrombocytopenia (15.2%), pneumonia (5.8%), general physical health deterioration (4.2%) and shortness of breath (4.2%).
Novartis International AG Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015
Oct 27 15
Novartis International AG reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2015. For the quarter, net sales from continuing operations was $12,265 million against $13,046 million a year ago. Income from associated companies was $120 million against $938 million a year ago. Net income from continuing operations was $1,812 million against $3,102 million a year ago. Net income attributable to the company was $1,888 million against $3,223 million a year ago. Diluted earnings per share from continuing operations were $0.74 against $1.25 a year ago. Total diluted earnings per share were $0.77 against $1.31 a year ago. Total cash flows from operating activities were $3,126 million against $4,011 million a year ago. Purchase of property, plant & equipment was $579 million against $668 million a year ago. Purchase of intangible, financial and other non-current assets was $201 million against $331 million a year ago.
For the nine months, net sales from continuing operations were $36,920 million against $39,289 million a year ago. Operating income from continuing operations was $7,300 million against $8,738 million a year ago. Net income from continuing operations was $5,974 million against $8,279 million a year ago. Net income attributable to shareholders was $16,729 million against $8,719 million a year ago. Diluted earnings per share from continuing operations were $2.44 against $3.32 a year ago. Total diluted earnings per share were $6.84 against $3.52 a year ago. Total cash flows from operating activities were $7,740 million against $8,692 million a year ago. Purchase of property, plant & equipment was $1,614 million against $1,794 million a year ago. Purchase of intangible, financial and other non-current assets was $923 million against $775 million a year ago.
Similar Private Companies By Industry
Recent Private Companies Transactions